Molecular Partners has initiated a program to develop a multitargeted approach to neutralizing COVID-19 infection using its DARPin protein platform.
According to a company press release, a DARPin candidate will be chosen based on its ability to block binding of the human ACE2 receptor, to block binding of a protease essential for spike protein activation and to prevent the change in the protein before injecting viral RNA into human cells.
“Among the many efforts underway, a DARPin therapeutic that can neutralize multiple sites of the viral spike protein in a (Read more...)
Uncategorized